Risk Factors for the Progression of Mild Cognitive Impairment in Different Types of Neurodegenerative Disorders
Table 3
Logistic regression model of variables associated with conversion to dementia in the AD (a), LBD (b), and VaD (c) cases of the MCI cohort.
(a) Subgroup of AD
OR
2.50%
97.50%
value
(Intercept)
0.008
1.00E − 04
0.309
0.013
Age
1.058
1.010
1.112
0.021
Gender
0.424
0.202
0.874
0.021
CDR-SB
1.395
1.030
1.913
0.034
Hyperlipidemia
0.761
0.364
1.569
0.462
Depression
1.124
0.419
2.985
0.814
Antidementia agents
3.411
1.572
7.789
0.003
Hypnotic agents
1.800
0.808
4.051
0.151
(b) Subgroup of LBD
OR
2.5%
97.50%
value
(Intercept)
0
0
0.529
0.067
Age
1.186
1.021
1.446
0.051
Gender
0.143
0.012
1.009
0.080
CDR-SB
1.079
0.486
2.358
0.845
Dyslipidemia
0.321
0.045
1.825
0.218
Depression
7.221
0.720
106.364
0.109
Antidementia agents
66.025
7.839
1340.956
0.001
Hypnotic agents
0.410
0.057
2.3819
0.337
(c) Subgroup of VaD
OR
2.50%
97.5%
value
(Intercept)
0.000
0.000
0.068
0.009
Age
1.106
1.030
1.203
0.010
Gender
0.563
0.129
2.233
0.421
CDR-SB
2.172
1.229
4.309
0.015
Hyperlipidemia
0.459
0.131
1.550
0.211
Depression
8.786
1.059
101.545
0.057
Hypnotic agents
0.820
0.216
2.934
0.762
AD: Alzheimer’s disease; VaD: vascular dementia; LBD: Lewy body diseases; CDR-SB: Clinical Dementia Rating-Sum of Boxes. Remark: hypnotic agents indicate benzodiazepines and nonbenzodiazepine hypnotic agents. Antidementia agents were not reimbursed for VaD patients in Taiwan health insurance system. They were not analyzed in the model due to sparsity.
